MDM2 and neuroblastoma: Our study as well as the exceptionally low rate of TP53 mutations in neuroblastoma provides the rationale for testing combinatorial inhibition of ALK and MDM2 as a therapeutic approach for treating TP53 wild-type neuroblastomas with aberrantly activated ALK.